Dulaglutide's Blood Sugar Benefits Linked to Leptin and Obestatin Changes, Not Just Weight Loss
In type 2 diabetes patients, dulaglutide improved blood sugar control through hormonal changes in leptin and obestatin rather than through weight or fat loss alone.
Quick Facts
What This Study Found
Decreases in leptin and increases in obestatin independently predicted HbA1c reduction with dulaglutide, while changes in BMI or abdominal fat were not associated with glycemic improvement. Responders showed greater beta-cell function improvement and more pronounced food craving reductions.
Key Numbers
n=82 enrolled, 67 completed; dulaglutide 0.75 mg weekly; 24 weeks; leptin decrease and obestatin increase independently associated with HbA1c reduction
How They Did This
24-week prospective observational study. 82 T2DM patients with HbA1c ≥7.0% received dulaglutide 0.75 mg weekly. Abdominal CT, food craving questionnaires, and fasting levels of leptin, adiponectin, obestatin, ghrelin, and resistin assessed at baseline and week 24. Responders defined as HbA1c reduction ≥0.5% and/or HbA1c <7.0%. Multivariable regression identified predictors of glycemic improvement.
Why This Research Matters
Demonstrates that GLP-1 drug benefits extend beyond weight loss through hormonal modulation of leptin and obestatin, potentially enabling biomarker-based prediction of treatment response.
The Bigger Picture
As GLP-1 drugs become first-line treatments for diabetes and obesity, understanding their mechanisms beyond weight loss is increasingly important. This study adds evidence that GLP-1 receptor agonists modulate a network of appetite-related hormones and adipokines. The identification of leptin and obestatin as independent predictors of response could contribute to personalized medicine approaches — testing hormone levels to guide GLP-1 therapy decisions.
What This Study Doesn't Tell Us
Single-arm, no control group; n=67 completers; low-dose only (0.75 mg); 24-week duration; observational (association not causation); 18% dropout.
Questions This Raises
- ?Do leptin and obestatin changes also predict response to other GLP-1 drugs like semaglutide or tirzepatide?
- ?Would higher-dose dulaglutide (1.5 mg) produce even greater hormonal shifts and better glycemic outcomes?
- ?Could baseline leptin or obestatin levels be used prospectively to predict who will respond to GLP-1 therapy?
Trust & Context
- Key Stat:
- Leptin decrease + obestatin increase = glycemic improvement Changes in these two hormones independently predicted HbA1c reduction, while changes in BMI or abdominal fat did not
- Evidence Grade:
- This is a prospective observational study with 67 completers, published in a diabetes journal. While well-designed with CT imaging and comprehensive hormone panels, the lack of a control group and modest sample size place it at moderate evidence strength.
- Study Age:
- Published in 2025, this is very recent research that provides new mechanistic insights into how GLP-1 drugs work beyond weight loss — a timely question as these drugs see explosive growth in clinical use.
- Original Title:
- Glycemic Improvement with Low-Dose Dulaglutide Is Associated with Leptin and Obestatin Modulation in Type 2 Diabetes Mellitus.
- Published In:
- Diabetes & metabolism journal (2025)
- Authors:
- Jung, Inha, Choi, Hangseok, Choi, In Young, Cho, Hyun Joo, Park, So Young, Lee, Da Young, Seo, Ji A, Kim, Nan Hee, Yu, Ji Hee
- Database ID:
- RPEP-11662
Evidence Hierarchy
Frequently Asked Questions
What is obestatin and why does it matter here?
Obestatin is a peptide hormone produced in the stomach that's involved in appetite regulation and energy balance. In this study, patients whose obestatin levels went up during dulaglutide treatment had better blood sugar improvement. This suggests obestatin may play a role in how GLP-1 drugs improve metabolism — a connection that wasn't previously well understood.
Does this mean you can benefit from dulaglutide even without losing weight?
Yes, that's one of the key implications. The study found that changes in BMI or belly fat were not what predicted blood sugar improvement — it was hormonal changes in leptin and obestatin. This means some patients may get significant blood sugar benefits from GLP-1 drugs even if their weight doesn't change much.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-11662APA
Jung, Inha; Choi, Hangseok; Choi, In Young; Cho, Hyun Joo; Park, So Young; Lee, Da Young; Seo, Ji A; Kim, Nan Hee; Yu, Ji Hee. (2025). Glycemic Improvement with Low-Dose Dulaglutide Is Associated with Leptin and Obestatin Modulation in Type 2 Diabetes Mellitus.. Diabetes & metabolism journal. https://doi.org/10.4093/dmj.2025.0681
MLA
Jung, Inha, et al. "Glycemic Improvement with Low-Dose Dulaglutide Is Associated with Leptin and Obestatin Modulation in Type 2 Diabetes Mellitus.." Diabetes & metabolism journal, 2025. https://doi.org/10.4093/dmj.2025.0681
RethinkPeptides
RethinkPeptides Research Database. "Glycemic Improvement with Low-Dose Dulaglutide Is Associated..." RPEP-11662. Retrieved from https://rethinkpeptides.com/research/jung-2025-glycemic-improvement-with-lowdose
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.